Evidence map›Paper›PMID 28931031›Full record

Trial reportPloS one2017

Reducing therapeutic misconception: A randomized intervention trial in hypothetical clinical trials.

Paul P Christopher, Paul S Appelbaum, Debbie Truong, Karen Albert, Louise Maranda, Charles Lidz

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. COVID-19 clinical trials: who is likely to participate and why?Journal of comparative effectiveness research · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Paul P ChristopherDepartment of Psychiatry & Human Behavior, Alpert Medical School, Brown University, Providence, RI, United States of America.ORCID http://orcid.org/0000-0001-5055-5379
Paul S AppelbaumDivision of Law, Ethics, and Psychiatry, Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, United States of America.
Debbie TruongDepartment of Psychiatry, University of Massachusetts Medical School, Worcester, MA, United States of America.
Karen AlbertDepartment of Psychiatry, University of Massachusetts Medical School, Worcester, MA, United States of America.
Louise MarandaDepartment of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, United States of America.
Charles LidzDepartment of Psychiatry, University of Massachusetts Medical School, Worcester, MA, United States of America.

Funding

Therapeutic Misconception and Scientific ReframingR21AT008648 · NCCIH · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LIDZ, CHARLES W · 2014 to 2015
$454k
NCCIH NIH HHS R21 AT008648
6 · The paper itself

Abstract

backgroundParticipants in clinical trials frequently fail to appreciate key differences between research and clinical care. This phenomenon, known as therapeutic misconception, undermines informed consent to clinical research, but to date there have been no effective interventions to reduce it and concerns have been expressed that to do so might impede recruitment. We determined whether a scientific reframing intervention reduces therapeutic misconception without significantly reducing willingness to participate in hypothetical clinical trials.

methodsThis prospective randomized trial was conducted from 2015 to 2016 to test the efficacy of an informed consent intervention based on scientific reframing compared to a traditional informed consent procedure (control) in reducing therapeutic misconception among patients considering enrollment in hypothetical clinical trials modeled on real-world studies for one of five disease categories. Patients with diabetes mellitus, hypertension, coronary artery disease, head/neck cancer, breast cancer, and major depression were recruited from medical clinics and a clinical research volunteer database. The primary outcomes were therapeutic misconception, as measured by a validated, ten-item Therapeutic Misconception Scale (range = 10-50), and willingness to participate in the clinical trial.

results154 participants completed the study (age range, 23-87 years; 92.3% white, 56.5% female); 74 (48.1%) had been randomized to receive the experimental intervention. Therapeutic misconception was significantly lower (p = 0.004) in the scientific reframing group (26.4, 95% CI [23.7 to 29.1] compared to the control group (30.9, 95% CI [28.4 to 33.5], and remained so after controlling for education (p = 0.017). Willingness to participate in the hypothetical trial was not significantly different (p = 0.603) between intervention (52.1%, 95% CI [40.2% to 62.4%]) and control (56.3%, 95% CI [45.3% to 66.6%] groups.

conclusionsAn enhanced educational intervention augmenting traditional informed consent led to a meaningful reduction in therapeutic misconception without a statistically significant change in willingness to enroll in hypothetical clinical trials. Additional study of this intervention is required in real-world clinical trials.

Indexed as

AdultAgedAged, 80 and overBiomedical ResearchClinical Trials as TopicFemaleHumansInformed ConsentMaleMiddle AgedProspective StudiesTherapeutic MisconceptionYoung Adult

Identifiers

PMID28931031
PMCPMC5607126

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.